Precision Denervation Powered by Real-Time Nerve Sensing
Autonomix Illuminates the Nervous System with First-of-Its-Kind Technology
Precision Denervation Powered by Real-Time Nerve Sensing
Autonomix is developing the world’s first GPS for the nervous system, a first-in-class, breakthrough platform technology that introduces real-time, intra-procedural nerve mapping. For the first time ever, this innovation has the potential to create a new paradigm in therapeutic electrophysiology by enabling physicians to sense nerve activity and guide treatment precision, representing a groundbreaking advancement in the field of transvascular denervation.
Protected by exclusive rights to a rapidly growing global IP portfolio – including 18 patent families and more than 120 issued or pending applications worldwide – Autonomix is building a category-defining solution with the potential to unlock new treatments across cardiology, interventional pain management, pulmonology, gastroenterology, and more.
First-In-Class Precision
Detects and differentiates small, distributed nerve networks using high-sensitivity signal capture and local processing
120+ Patents Issued or Pending
Backed by a robust and globally protected IP portfolio covering 120+ patents issued or pending
Multi-Indication Platform
Designed to expand across a wide spectrum of therapeutic areas with high unmet need
Real-Time Feedback
Identifies nerve activity in real-time to guide clinicians to deliver effective therapy and confirm successful ablation
Personalized Therapy
Facilitates tailored therapy by mapping nerve activity so treatment can be adjusted based on individual physiology
A Growing List of Studies and Clinical Results
Autonomix’s initial focus is on interventional chronic pain management associated with severe pancreatic cancer in a first-in-human proof-of-concept study (PoC 1) to validate the concept.
Following promising initial results from PoC 1, the study has expanded to a follow-on phase that will double the potential addressable market beyond pancreatic cancer pain. The follow-on phase (PoC 2) will assess additional visceral cancers that signal pain through the Celiac Plexus and earlier stage pancreatic cancers with moderate to severe pain. This phase will provide a concentrated focus on interventional cancer pain management applications like pancreatic, gall bladder, liver, and bile duct, with potential further expansion in oncology, gastroenterology, and other sectors.
Insights and results from these valuable studies will guide the design of future clinical studies, including planned U.S. trials.
Clinical Results
Positive Topline Results from PoC 1 Highlights Impact Across All Three Core Areas: Pain Reduction, Opioid Use and Quality of Life, with No Device or Procedure-Related Serious Adverse Events
- Initial trial phase achieved key learnings and met all study objectives
- Statistically significant pain relief as early as 24-hours post procedure, providing patients with rapid relief
- Pain reduction remained consistently positive at 7-days and 4-6 weeks post-procedure
- Patients reported an improved quality of life during end-stage cancer while reducing their use of opioids
- The procedure demonstrated a strong safety profile with no device or procedure-related serious adverse events1
1. As to be expected in seriously ill patient populations, there were 8 serious adverse events not related to the device or procedure (6 subjects succumbed to their disease before the 4-6 week follow up and 2 events related to disease progression resulting in hospitalization)
First-Hand Perspectives: Physicians & Patients
Hear from the primary investigator and participating patients about their experience in the PoC 1 study and the potential impact of this breakthrough technology.
Who We Help.
Advancing Innovation in Nervous System Technologies
Autonomix’s singular purpose is to transform patient outcomes by revolutionizing how diseases involving the peripheral nervous system are diagnosed and treated.
Initially, efforts are centered on pancreatic cancer patients suffering from intractable pain. Current therapies that primarily rely on opioids or invasive ethanol neurolysis can provide only limited relief and may lead to risky side effects.
Autonomix aims to deliver safe, effective, and lasting relief through a precision-guided, minimally invasive procedure to improve patient outcomes and quality of life. Once validated, the platform can be expanded to treat a wide array of conditions where overactive nerves play a critical role.
Robust and Globally-Protected IP Portfolio
Autonomix holds 120+ issued or pending patents spanning technologies, methods, and applications that underscore a breadth of application and expansion opportunities for Autonomix’s platform technology.
The Autonomix Opportunity
Proof-of-Concept in Lead Indication Unlocks a $100 Billion Market Potential
Autonomix is developing the world’s first GPS for the nervous system and approaching therapeutic electrophysiology in a new way by targeting shared vasculature and nerve plexuses involved in disease progression and symptom generation.
Platform Expansion Across Therapeutic Categories
Other Disorders May Also Include: Tumor Progression, Digestive Disorders, Urinary Tract Disorders, Metabolic Disorders and Chronic Inflammation.